One of the hallmarks of Alzheimer's disease is the accumulation of a peptide in the brain known as amyloid beta. A new study ...

The U.S. Food and Drug Administration (FDA) recently approved a subcutaneous starter dose of Leqembi, a drug indicated to treat mild cases of Alzheimer’s disease. With the new approval, people can use ...

A colored image of mitochondria in a pancreas cell, via transmission electron microscopy. (Callista Images/Connect ...

By detecting the subtle brain changes and damage to nerve cells years before memory or language issues surface, the blood test allows patients to seek treatment during the window when therapies are ...

Kisunla is designed to help slow the progression of early symptomatic Alzheimer's by targeting the brain to break up and ...

A new study reveals how hyperphosphorylated tau causes reverse electron transport in mitochondria, driving Alzheimer's ...

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has outlined the scientific rationale supporting its lead drug candidate Xanamem® ...

Many people with less common forms of Alzheimer's disease may not qualify for newer anti-amyloid treatments designed to slow ...

COVID-19 may increase the risk of Alzheimer’s disease, especially for those who experience a severe infection. COVID-19 causes inflammation and other physiological changes in the brain that are ...

Oshkosh’s Walk to End Alzheimer’s is Sept. 26 at Lakeshore Pavilion, raising funds for care, support and research.